VOL. 25 - NO. 21
MAY 24 - 31, 2020
PO BOX 13283
OAKLAND, CA 94661-0283

510.595.7777 FAX

Joint Forces Journal is published privately, and in no way is connected with DoD, the U.S. Army, Navy, Air Force or Coast Guard. This website and the printed newspaper are intended for the members of the Armed Forces and their families. Contents do not necessarily reflect official views of the U.S. Government, the Department of Defense or the U.S. Army, Navy, Air Force or Coast Guard, and do not imply endorsements thereof. The marital status, physical handicap, political affiliation, or any other non-merit factor of the purchases, user or patron for advertisers prohibited. If a violation or rejection of this equal opportunity policy by an advertiser is confirmed, the publisher shall refuse to print advertising from that source until the violation is corrected. Editorial content is prepared and edited privately, and is provided by the Public Affairs Office of U.S. Army, Navy, Air Force and Coast Guard installations. Correspondence and material for publication should be addressed to: Editor, Joint Forces Journal, P.O. Box 13283, Oakland, CA, 94661-0283. Deadline for receiving articles and photos is 3 p.m. Monday for publication on Friday of that week. Joint Forces Journal editorial policy is to use bylines and photo credits where applicable and when submitted.

Meet the Army Lieutenant Racing to Develop a Coronavirus Vaccine

Mar 27, 2020
by Patricia Kime
Ten months ago, Ethan Green walked across a stage at Wake Forest University in Winston-Salem, North Carolina, to accept a bachelor's degree in biology and a commission from the U.S. Army.

Recently, Green, now a second lieutenant and doctoral candidate at the Uniformed Services University of the Health Sciences, climbed out of bed at 2 a.m. for his daily trek to a lab at the Walter Reed Army Institute of Research (WRAIR) in Silver Spring, Maryland. There, he planned to spend the day harvesting proteins found in the SARS-CoV-2 coronavirus so they could be used for developing a vaccine against the disease it causes, COVID-19.

For the only active-duty member on WRAIR's coronavirus vaccine development team, the job fulfills a dream he's had since he was 14: to be an Army microbiologist.

"The nature of what I'm doing, it's an amazing opportunity, and I thank God every day that I'm doing it. It makes me really sad that I have to -- I'd much rather be bored out of my mind in the lab -- but it has filled me with this immense purpose," Green said.

Researchers at WRAIR and across the globe have been working since Jan. 10 on initiatives to develop vaccines, diagnostic tests and treatments for COVID-19. That's the date Chinese scientists first published the genetic sequence of the novel coronavirus, which gave them a map for tackling the problem.

The novel coronavirus first appeared in Wuhan, China, in mid-December and, as of March 24, had sickened more than 407,000 people worldwide and killed 18,227, according to Johns Hopkins University.

The U.S. Army, WRAIR and U.S. Army Medical Research and Development Command launched an all-out effort to develop diagnostic tests, as well as a vaccine. At WRAIR, the effort was built largely on the institute's earlier work on vaccines for Ebola, Zika and the Middle East Respiratory Syndrome, or MERS, coronavirus.

"The Emerging Infectious Disease Branch was created by our command ... a year and a half ago because we were having to quickly pull things together from different departments for Ebola and Zika and MERS. So we created this department to be already primed and ready to go," branch director Dr. Kayvon Modjarrad said.

WRAIR is developing a protein vaccine, which targets a portion of the virus -- its protein shell -- that includes the nubs seen in photos of the virus and several other types of protein.

Green said the idea is to isolate the proteins and then "more or less throw human antibodies at them and see what sticks."

"What we are really looking at is a vaccine we could give to soldiers at basic training, stab them, shoot them up with the vaccine and never have to worry about it again," he explained.

Modjarrad said the branch also is determining whether an adjuvant -- a separate substance given along with the protein vaccine -- will bolster immune response. Testing is currently underway in mice at WRAIR on a vaccine and adjuvants, he added.

As of March 24, the Defense Department had 321 total active cases of COVID-19, also known as the novel coronavirus, within the DoD: 174 military, 61 dependents, 59 civilians and 27 Defense Department contractors. In addition, four military members and one civilian have recovered. One contractor died March 21.

The Department of Veterans Affairs had 296 cases as of March 24, a 45% increase from the day before, and four deaths, including two in New York City.

No one knows whether the SARS-CoV-2 coronavirus will continue its path to infecting many on the planet or if it will become a seasonal illness similar to influenza. Modjarrad said the goal is to have a vaccine in place by next winter in case COVID-19 becomes a seasonal event.

"What the different vaccine developers, including us, are trying to do is to position ourselves so we get through the initial studies and be ready for testing by the next winter season," he said.

Several private companies are working on a COVID-19 vaccine and are in various stages of development, including Moderna Therapeutics, CureVac, GlaxoSmithKline, Inovio Pharmaceuticals, Johnson & Johnson and Sanofi.

Recently, volunteers received the first dose of a vaccine developed by Moderna Therapeutics. It also will take a year to complete the trials to determine safety and effectiveness.

Green, who had been working on a universal influenza vaccine before being pulled to assist with the coronavirus vaccine effort, is optimistic that there will be a solution.

"We'll be able to get one before the year is out, at least the clinical trials, and that's if everything goes wrong, like fires, earthquakes and Godzilla attacks. We'll get something out," he said.

* * * * *

Photo caption: Army 2nd Lt. Ethan Green, a doctoral student at the Uniformed Services University of the Health Sciences, is working on the effort to develop a vaccine for the COVID-19, the only active-duty military member on the Walter Reed Army Institute of Research team. (Courtesy Ethan Green)


A Very Good Boy Named 'The Dude' Sniffs Out Bombs on Patrol with US Troops

Marine Corps May Replace Infantry M27s with the Army's Next Generation Squad Weapon

Grand Haven Coast Guard Festival Canceled Due to Coronavirus Crisis

Eglin Orders Brief Suspension of Flight Ops Following F-35, F-22 Crashes

TRAVEL & ENTERTAINMENT: Livermore Valley Performing Arts Center Shakes Up Its Calendar

Coast Guard Cutter Diligence to Leave Wilmington for Good on Memorial Day

Astronauts Arrive for NASA's 1st Home Launch in Decade

Navy Sends Subs to Sea as Message to China

TRAVEL & ENTERTAINMENT: Smuin Ballet Announces Free Streaming of Rex Wheeler’s Dave Brubeck Tribute “Take Five”